Back to search

Boston University

Assessing treatment benefit in the presence of placebo response using the Sequential Parallel Comparison Design

Abstract

dc:description.abstract

In clinical trials, placebo response is considered a beneficial effect arising from multiple factors, including the patient’s expectations for the treatment. Due to the presence of placebo response, the classical parallel design often fails to declare an efficacious treatment. The Sequential Parallel Comparison Design (SPCD), a two-stage design where the first stage is a classical parallel trial, followed by another parallel trial among placebo patients from the first stage, was proposed to mitigate the placebo response. In SPCD, in lieu of treatment effect, a weighted average of the mean treatment difference in Stage I among all randomized patients and the mean treatment difference in Stage II among placebo non-responders was proposed as the efficacy measure. However, by mixing two possibly different populations, this weighted average lacks interpretability, the choice of weight remains controversial, and the classification of patients into placebo responders and non-responders via hard criterion-based rule warrants careful consideration. In this work, we first elaborate and study the shortcomings surrounding this efficacy measure, which motivates us to propose causal estimands for clinically meaningful principal strata under the principal stratification framework. To make the estimands identifiable, we invoke a set of assumptions and introduce two sensitivity parameters. Meanwhile, in the absence of a clinically proven criterion for classifying responders and non-responders, we additionally suggest estimating the response status and sensitivity parameters via the Expectation-Maximization (EM) algorithm by treating the principal strata as full latent characteristics. Next, we further refine and alternatively propose a more consistent and sophisticated EM procedure for classification, point estimation, and hypothesis testing. Finally, we evaluate our methods with extensive simulation studies and apply them to an actual SPCD study of antidepressant therapy to assess the benefit of low-dose aripiprazole adjunctive to antidepressant therapy treatment, the ADAPT-A trial. In conclusion, we believe this is an important step toward a more rigorous and transparent approach to evaluating the treatment benefit in the presence of placebo response.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy
Level thesis:degree_level
doctoral
Discipline thesis:degree_discipline
Biostatistics
Grantor
Boston University
Year dc:date.issued
2022

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Liu, Xiaoyan
Advisor dc:contributor.advisor
  • Doros, Gheorghe
ORCID dc:identifier.orcid

Subjects

dc:subject × 6

Rights

dc:rights
Statement dc:rights
  • Attribution 4.0 International
Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/46919

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Liu, Xiaoyan. Assessing treatment benefit in the presence of placebo response using the Sequential Parallel Comparison Design. doctoral thesis, Boston University, 2022. https://hdl.handle.net/2144/46919